Riskpilot← Back to searchSign inGet full accessLymed Oy
OYActiveY-tunnus 0935988-8Pyhäjärvenkatu 5-AManufacture of outerwear · NACE 1421Est. 1993— employees
Revenue 2024
EUR 3,5M
EBITDA margin
19.9%
Equity ratio
60.7%
Financial strength
Net profit 2024
EUR 520K
+95% vs 2023
| Revenue | EUR 3,5M | — |
| EBITDA | EUR 698K | — |
| Net profit | EUR 520K | +95% |
| Total assets | EUR 3,7M | +1% |
| Equity | EUR 2,2M | +20% |
| Employees | — | — |
Legal name
Lymed Oy
Y-tunnus number
0935988-8
Legal form
Osakeyhtiö
NACE code
1421 · Manufacture of outerwear
Founded
1. syyskuuta 1993
Share capital
EUR 21 025
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Yhtiön toimialana on lääkinnällisiin tarkoituksiin käytettävien ja muiden vaatteiden suunnittelu, valmistus, maahantuonti ja myynti.
Address
Pyhäjärvenkatu 5-A
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 926 | 2 696 | 2 940 | 0 | 3 508 |
| Staff expenses | −1 630 | −1 761 | −1 851 | −193 904 | −1 965 |
| EBITDA | 424 | 249 | 151 | 0 | 698 |
| Depreciation & amort. | −105 | −82 | −21 | −15 | −20 |
| EBIT | 319 | 166 | 130 | 361 | 678 |
| Net financials | −9 | −14 | −20 | 0 | −27 |
| Profit before tax | 310 | 153 | 110 | 0 | 650 |
| Tax | 62 | 31 | 22 | −0 | 130 |
| Net profit | 248 | 122 | 88 | 266 | 520 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 933 | 3 688 | 3 682 | 3 657 | 3 700 |
| Equity | 1 834 | 1 805 | 1 748 | 1 874 | 2 245 |
| Long-term debt | 23 | 1 257 | 1 114 | 949 | 810 |
| Short-term debt | 1 076 | 626 | 821 | 834 | 645 |
| Total debt | 1 099 | 1 883 | 1 935 | 1 783 | 1 456 |
EBITDA margin
19.9%
This company
15.8%
Market median
+26% vs market
20202024
Equity ratio
60.7%
This company
38.2%
Market median
+59% vs market
20202024
Return on equity
23.2%
This company
18.4%
Market median
+26% vs market
20202024
Net profit margin
14.8%
This company
8.1%
Market median
+83% vs market
20202024
Asset turnover
0.95×
This company
1.12×
Market median
+15% vs market
20202024
Debt / equity
0.65×
This company
0.62×
Market median
+5% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EE Chief Executive Officer | Chief Executive Officer | 2023 |
| Former (2) | ||
RJ Audit | Audit | 2021 – 2023 |
MT | Audit | 2010 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2013 | |
| Chairperson | 2023 | |
| Board of Directors | 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Lymed Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Roni Juhani Kyrkkö | Audit | 0 companies |
| Essi Eveliina Toikka | Chief Executive Officer | 0 companies |
| Mirja Tuulikki Juusela | Audit | 0 companies |
| Tanu Ilmari Toikka | Board of Directors | 0 companies |
| Teija Hannele Toikka | Chairperson | 0 companies |
| Timo Tapani Toikka | Board of Directors | 0 companies |